Top

Published in:

01-05-2016 | Nephrology - Original Paper

Uremia-caused changes of ghrelin system in hippocampus may be associated with impaired cognitive function of hippocampus

Authors: Zhian Lv, Jie Gao, Li Wang, Zhao Chen, Haozheng Yuan, Xiaoqin Ma, Jiamei Lu, Jianrui Lv, Xili Wu, Lei Zhang, Linting Wei, Rongliang Xue, Rongguo Fu, Liqun Ma

Published in: International Urology and Nephrology | Issue 5/2016

Abstract

Purpose

Hippocampus plays an important role in spatial learning and memory. Ghrelin, a brain-gut peptide, participates in the mnestic functions of hippocampus through its receptor growth hormone secretagogue receptor (GHS-R) distributed in hippocampus. This study was to investigate whether there was a correlation between the changes of ghrelin system in hippocampus and the spatial cognitive impairment caused by chronic renal failure (CRF).

Methods

Sprague–Dawley rats (male, 180 ± 10 g, 7–8 weeks old) were randomly classified into CRF group and control group (n = 18 per group). The CRF model was constructed by 5/6 nephrectomy and the controls treated with sham operation. By the 8th week after the surgery, the spatial cognitive function of rats was assessed by Morris water-maze test (MWM), the protein expression of ghrelin and GHS-R in the hippocampus by immunohistochemistry, and the mRNA expression by real-time PCR. Statistical analysis was performed using ANOVA, Student–Newman–Keuls-q test and Pearson correlation analysis, and P < 0.05 was considered significant.

Results

Compared with the controls, the time spent in “platform” quadrant (TSPQ) of rats with CRF was decreased, but the escape latency (EL) was increased significantly in MWM, and meanwhile the protein and mRNA expression of ghrelin and GHS-R in hippocampus was also increased significantly (P < 0.05 or P < 0.01). Correlation analysis suggested that the TSPQ was negatively but the EL was positively correlated with the mRNA expression of ghrelin and GHS-R (P < 0.01).

Conclusion

The CRF-caused changes of ghrelin system in hippocampus might be correlated with the CRF-caused cognitive function impairment.

Murray AM, Tupper DE, Knopman DS, Gilbertson DT, Pederson SL, Li S, Smith GE, Hochhalter AK, Collins AJ, Kane RL (2006) Cognitive impairment in hemodialysis patients is common. Neurology 67(2):216–223. doi:10.1212/01.wnl.0000225182.15532.40 CrossRefPubMed

Madan P, Kalra OP, Agarwal S, Tandon OP (2007) Cognitive impairment in chronic kidney disease. Nephrol Dial Transpl 22(2):440–444. doi:10.1093/Ndt/Gfl572 CrossRef

Burgess N, Maguire EA, O’Keefe J (2002) The human hippocampus and spatial and episodic memory. Neuron 35(4):625–641. doi:10.1016/S0896-6273(02)00830-9 CrossRefPubMed

Fujisaki K, Tsuruya K, Yamato M, Toyonaga J, Noguchi H, Nakano T, Taniguchi M, Tokumoto M, Hirakata H, Kitazono T (2014) Cerebral oxidative stress induces spatial working memory dysfunction in uremic mice: neuroprotective effect of tempol. Nephrol Dial Transplant 29(3):529–538. doi:10.1093/ndt/gft327 CrossRefPubMed

Horvath TL, Diano S, Sotonyi P, Heiman M, Tschop M (2001) Minireview: ghrelin and the regulation of energy balance—a hypothalamic perspective. Endocrinology 142(10):4163–4169. doi:10.1210/endo.142.10.8490 PubMed

Chen CY, Asakawa A, Fujimiya M, Lee SD, Inui A (2009) Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev 61(4):430–481. doi:10.1124/pr.109.001958 CrossRefPubMed

Xu JJ, Wang SZ, Lin YT, Cao LL, Wang R, Chi ZF (2009) Ghrelin protects against cell death of hippocampal neurons in pilocarpine-induced seizures in rats. Neurosci Lett 453(1):58–61. doi:10.1016/j.neulet.2009.01.067 CrossRefPubMed

Zigman JM, Jones JE, Lee CE, Saper CB, Elmquist JK (2006) Expression of ghrelin receptor mRNA in the rat and the mouse brain. J Comp Neurol 494(3):528–548. doi:10.1002/Cne.20823 CrossRefPubMedPubMedCentral

Carlini VP, Varas MM, Cragnolini AB, Schioth HB, Scimonelli TN, de Barioglio SR (2004) Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. Biochem Biophys Res Commun 313(3):635–641. doi:10.1016/j.bbrc.2003.11.150 CrossRefPubMed

10.

Fu RG, Wang L, Yao GL, Xue RL, Ge H, Ren ST, Ma LQ, Jiang HL, Liu X (2012) Chronic renal failure impacts the expression of ghrelin and its receptor in hypothalamus and hippocampus. Ren Fail 34(8):1027–1032. doi:10.3109/0886022x.2012.708379 CrossRefPubMed

11.

Nunez J (2008) Morris water maze experiment. J Vis Exp. doi:10.3791/897

12.

Swanson LW (2004) Brain maps III: structure of the rat brain: an atlas with printed and electronic templates for data, models, and schematics, 3rd rev. edn. Elsevier, Amsterdam

13.

McElroy MW, Korol DL (2005) Intrahippocampal muscimol shifts learning strategy in gonadally intact young adult female rats. Learn Mem 12(2):150–158. doi:10.1101/Lm.86205 CrossRefPubMedPubMedCentral

14.

Al Banchaabouchi M, D’Hooge R, Marescau B, De Deyn PP (1999) Behavioural deficits during the acute phase of mild renal failure in mice. Metab Brain Dis 14(3):173–187CrossRefPubMed

15.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402(6762):656–660. doi:10.1038/45230 CrossRefPubMed

16.

Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotonyi P, Friedman JM, Liu HY, Pinto S, Colmers WF, Cone RD, Horvath TL (2003) The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37(4):649–661. doi:10.1016/S0896-6273(03)00063-1 CrossRefPubMed

17.

Braak H, Braak E, Yilmazer D, Bohl J (1996) Functional anatomy of human hippocampal formation and related structures. J Child Neurol 11(4):265–275CrossRefPubMed

18.

Mcclelland JL, Mcnaughton BL, Oreilly RC (1995) Why there are complementary learning-systems in the hippocampus and neocortex—insights from the successes and failures of connectionist models of learning and memory. Psychol Rev 102(3):419–457. doi:10.1037/0033-295x.102.3.419 CrossRefPubMed

19.

Lee I, Hunsaker MR, Kesner RP (2005) The role of hippocampal subregions in detecting spatial novelty. Behav Neurosci 119(1):145–153. doi:10.1037/0735-7044.119.1.145 CrossRefPubMed

20.

Lee I, Kesner RP (2004) Encoding versus retrieval of spatial memory: double dissociation between the dentate gyrus and the perforant path inputs into CA3 in the dorsal hippocampus. Hippocampus 14(1):66–76. doi:10.1002/hipo.10167 CrossRefPubMed

21.

Carlini VP, Monzon ME, Varas MM, Cragnolini AB, Schioth HB, Scimonelli TN, de Barioglio SR (2002) Ghrelin increases anxiety-like behavior and memory retention in rats. Biochem Biophys Res Commun 299(5):739–743. doi:10.1016/S0006-291x(02)02740-7 CrossRefPubMed

22.

Ferrini F, Salio C, Lossi L, Merighi A (2009) Ghrelin in central neurons. Curr Neuropharmacol 7(1):37–49CrossRefPubMedPubMedCentral

23.

Diano S, Farr SA, Benoit SC, McNay EC, da Silva I, Horvath B, Gaskin FS, Nonaka N, Jaeger LB, Banks WA, Morley JE, Pinto S, Sherwin RS, Xu L, Yamada KA, Sleeman MW, Tschop MH, Horvath TL (2006) Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci 9(3):381–388. doi:10.1038/Nn1656 CrossRefPubMed

24.

Carlini VP, Gaydou RC, Schioth HB, de Barioglio SR (2007) Selective serotonin reuptake inhibitor (fluoxetine) decreases the effects of ghrelin on memory retention and food intake. Regul Pept 140(1–2):65–73. doi:10.1016/j.regpep.2006.11.012 CrossRefPubMed

25.

Jiang H, Betancourt L, Smith RG (2006) Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Mol Endocrinol 20(8):1772–1785. doi:10.1210/Me.2005-0084 CrossRefPubMed

26.

Brouns R, De Deyn PP (2004) Neurological complications in renal failure: a review. Clin Neurol Neurosurg 107(1):1–16. doi:10.1016/j.clineuro.2004.07.012 CrossRefPubMed

27.

28.

Yoshimoto A, Mori K, Sugawara A, Mukoyama M, Yahata K, Suganami T, Takaya K, Hosoda H, Kojima M, Kangawa K, Nakao K (2002) Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 13(11):2748–2752. doi:10.1097/01.Asn.0000032420.12455.74 CrossRefPubMed

29.

Fu RG, Xue RL, Wang J, Ma LQ, Lv JR, Wang L, Yao GL, Ge H, Chen Z, Duan ZY, Wang YR (2012) Uremic anorexia and ghrelin expression in the amygdala. Neurosci Lett 527(1):50–54. doi:10.1016/j.neulet.2012.08.040 CrossRefPubMed

30.

Buhot HC, Martin S, Segu L (2000) Role of serotonin in memory impairment. Ann Med 32(3):210–221CrossRefPubMed

31.

Bannon MJ, Poosch MS, Yue X, Goebel DJ, Cassin B, Kapatos G (1992) Dopamine transporter messenger-RNA content in human substantia-nigra decreases precipitously with age. Proc Natl Acad Sci USA 89(15):7095–7099. doi:10.1073/pnas.89.15.7095 CrossRefPubMedPubMedCentral

Title: Uremia-caused changes of ghrelin system in hippocampus may be associated with impaired cognitive function of hippocampus
Authors: Zhian Lv
Jie Gao
Li Wang
Zhao Chen
Haozheng Yuan
Xiaoqin Ma
Jiamei Lu
Jianrui Lv
Xili Wu
Lei Zhang
Linting Wei
Rongliang Xue
Rongguo Fu
Liqun Ma
Publication date: 01-05-2016
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 5/2016
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-016-1228-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2016

Overexpression of CXCL3 can enhance the oncogenic potential of prostate cancer

Oncological outcomes and prognostic factors after nephron-sparing surgery in renal cell carcinoma

Is low magnesium a clue to arteriovenous fistula complications in hemodialysis?

Eculizumab for the treatment of atypical hemolytic uremic syndrome recurrence after kidney transplantation associated with complement factor H mutations: a case report with a 5-year follow-up

Predicting technique and patient survival over 12 months in peritoneal dialysis: the role of anxiety and depression

Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials